BACKGROUND: Radiotherapy for retroperitoneal sarcomas remains controversial and a technical challenge considering the threshold of contiguous critical organs tolerance. We performed consecutive RapidArc dosimetric plans in preoperative or postoperative setting. METHODS: A dosimetric study was carried out from six preoperative (group A) and four postoperative (group B) CT-scans, performed in 7 patients.Prescribed dose was 45 and 50 Gy for groups A and B, respectively. The planning target volume (PTV) was defined as the clinical target volume (CTV) plus 5 mm. The CTV encompassed the gross tumor volume (GTV) plus 10 mm or the tumoral bed. The dosimetric plans were optimized on a RapidArc Eclipse console using the progressive resolution algorithm, PRO version 8.8. Normalization method allowed the coverage of 99% of the PTV by 95% of the dose. RESULTS: Mean PTV were 2318.5 ± 2223.9 cc [range 348-6198 cc] and 698.3 ± 216.6 cc [range 463 -933 cc] for groups A and B, respectively. Plans were optimized for single arcs in group B and for single or two arcs in group A. The contralateral kidney volume receiving 5 Gy (V5Gy) was 21.5 ± 23.3% [range 0-55%] and 3.1 ± 2.6% [range 0-7.3%] for groups A and B, respectively. The mean dose received by 1% of the kidney (D1%) was 5.6 ± 2.4 Gy [range 3.6 -7.6 Gy] for group A and 5.4 ± 0.7 Gy [range 4.3-6 Gy] for group B. The volume of small bowel excluding the PTV (small bowel-PTV) that received 40 Gy and 30 Gy (V40Gy and V30Gy) in group A were 7.5 ± 4.4% [range 5.4-14.1%] and 18.5 ± 7.1% [range 10-30.4%], respectively.In group B, small bowel-PTV V40Gy and V30Gy were 4.7 ± 3.3% [range 3.3-8%] and 21.6 ± 7.5% [range 9.4-30%] respectively. In a second step, we treated two patients in the postoperative group. Treatment time delivery with one arc was 74 seconds. No severe acute toxicity was observed. CONCLUSION: RapidArc technology for retroperitoneal sarcomas showed acceptable dosimetric results in preoperative or postoperative clinical situation. From the first treated patients, acute tolerability was good to excellent.
BACKGROUND: Radiotherapy for retroperitoneal sarcomas remains controversial and a technical challenge considering the threshold of contiguous critical organs tolerance. We performed consecutive RapidArc dosimetric plans in preoperative or postoperative setting. METHODS: A dosimetric study was carried out from six preoperative (group A) and four postoperative (group B) CT-scans, performed in 7 patients.Prescribed dose was 45 and 50 Gy for groups A and B, respectively. The planning target volume (PTV) was defined as the clinical target volume (CTV) plus 5 mm. The CTV encompassed the gross tumor volume (GTV) plus 10 mm or the tumoral bed. The dosimetric plans were optimized on a RapidArc Eclipse console using the progressive resolution algorithm, PRO version 8.8. Normalization method allowed the coverage of 99% of the PTV by 95% of the dose. RESULTS: Mean PTV were 2318.5 ± 2223.9 cc [range 348-6198 cc] and 698.3 ± 216.6 cc [range 463 -933 cc] for groups A and B, respectively. Plans were optimized for single arcs in group B and for single or two arcs in group A. The contralateral kidney volume receiving 5 Gy (V5Gy) was 21.5 ± 23.3% [range 0-55%] and 3.1 ± 2.6% [range 0-7.3%] for groups A and B, respectively. The mean dose received by 1% of the kidney (D1%) was 5.6 ± 2.4 Gy [range 3.6 -7.6 Gy] for group A and 5.4 ± 0.7 Gy [range 4.3-6 Gy] for group B. The volume of small bowel excluding the PTV (small bowel-PTV) that received 40 Gy and 30 Gy (V40Gy and V30Gy) in group A were 7.5 ± 4.4% [range 5.4-14.1%] and 18.5 ± 7.1% [range 10-30.4%], respectively.In group B, small bowel-PTV V40Gy and V30Gy were 4.7 ± 3.3% [range 3.3-8%] and 21.6 ± 7.5% [range 9.4-30%] respectively. In a second step, we treated two patients in the postoperative group. Treatment time delivery with one arc was 74 seconds. No severe acute toxicity was observed. CONCLUSION: RapidArc technology for retroperitoneal sarcomas showed acceptable dosimetric results in preoperative or postoperative clinical situation. From the first treated patients, acute tolerability was good to excellent.
Authors: H L Gieschen; I J Spiro; H D Suit; M J Ott; D W Rattner; M Ancukiewicz; C G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2001-05-01 Impact factor: 7.038
Authors: Ching-Wei D Tzeng; John B Fiveash; Richard A Popple; J Pablo Arnoletti; Suzanne M Russo; Marshall M Urist; Kirby I Bland; Martin J Heslin Journal: Cancer Date: 2006-07-15 Impact factor: 6.860
Authors: Alberto Bossi; Ivo De Wever; Erik Van Limbergen; Bianca Vanstraelen Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-01 Impact factor: 7.038
Authors: Barbara Bussels; Laurence Goethals; Michel Feron; Didier Bielen; Steven Dymarkowski; Paul Suetens; Karin Haustermans Journal: Radiother Oncol Date: 2003-07 Impact factor: 6.280
Authors: Mary Koshy; Jerome C Landry; Joshua D Lawson; Charles A Staley; Natia Esiashvili; Rebecca Howell; Shahram Ghavidel; Lawrence W Davis Journal: Sarcoma Date: 2003
Authors: Falk Roeder; Alexis Ulrich; Gregor Habl; Matthias Uhl; Ladan Saleh-Ebrahimi; Peter E Huber; Daniela Schulz-Ertner; Anna V Nikoghosyan; Ingo Alldinger; Robert Krempien; Gunhild Mechtersheimer; Frank W Hensley; Juergen Debus; Marc Bischof Journal: BMC Cancer Date: 2014-08-27 Impact factor: 4.430